Induced pluripotent stem cell-derived cardiomyocytes as models for genetic cardiovascular disorders

Current Opinion in Cardiology

Volumn 26, Issue 3, 2011, Pages 223-229

  Josowitz, Rebecca ^a   Carvajal Vergara, Xonia ^b   Lemischka, Ihor R ^a,c   Gelb, Bruce D ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

^c Black Family Stem Cell Institute ^*  (United States)

Author keywords

hypertrophic cardiomyopathy; induced pluripotent stem cells; LEOPARD syndrome; long QT syndrome

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; RAS PROTEIN;

ARTICLE; CARDIOVASCULAR DISEASE; DISEASE ASSOCIATION; EPIGENETICS; GENE EXPRESSION; GENETIC TRANSFECTION; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; HUMAN; LEOPARD SYNDROME; LONG QT SYNDROME; NONHUMAN; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PURIFICATION; SIGNAL TRANSDUCTION;

CARDIOVASCULAR DISEASES; CELL DIFFERENTIATION; FIBROBLASTS; HUMANS; INDUCED PLURIPOTENT STEM CELLS; LONG QT SYNDROME; MODELS, GENETIC; MYOCYTES, CARDIAC;

EID: 79955053031     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/HCO.0b013e32834598ad     Document Type: Article

References (36)

1. Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131:861-872. (Pubitemid 350138099)
2. Yu J, Vodyanik MA, Smuga-Otto K, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007; 318:1917-1920.
3. Wernig M, Lengner CJ, Hanna J, et al. A drug-inducible transgenic system for direct reprogramming of multiple somatic cell types. Nat Biotechnol 2008; 26:916-924.
4. Stadtfeld M, Nagaya M, Utikal J, et al. Induced pluripotent stem cells generated without viral integration. Science 2008; 322:945-949.
5. Woltjen K, Michael IP, Mohseni P, et al. piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. Nature 2009; 458:766-770.
6. Ichida JK, Blanchard J, Lam K, et al. A small-molecule inhibitor of tgf-Beta signaling replaces sox2 in reprogramming by inducing nanog. Cell Stem Cell 2009; 5:491-503.
7. Warren L, Manos PD, Ahfeldt T, et al. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 2010; 7:18-30.
8. Maherali N, Hochedlinger K. Guidelines and techniques for the generation of induced pluripotent stem cells. Cell Stem Cell 2008; 3:595-605.
9. Itskovitz-Eldor J, Schuldiner M, Karsenti D, et al. Differentiation of human embryonic stem cells into embryoid bodies compromising the three embryonic germ layers. Mol Med 2000; 6:88-95.
10. Police XUC, Hassanipour S, Gold MJ. Cardiac bodies: a novel culture method for enrichment of cardiomyocytes derived from human embryonic stem cells. Stem Cells Develop 2006; 15:631-639.
11. Yang L, Soonpaa MH, Adler ED, et al. Human cardiovascular progenitor cells develop from a KDR+ embryonic-stem-cell-derived population. Nature 2008; 453:524-528. (Pubitemid 351733312)
12. Willems E, Bushway PJ, Mercola M. Natural and synthetic regulators of embryonic stem cell cardiogenesis. Pediatr Cardiol 2009; 30:635-642.
13. Huber I, Itzhaki I, Caspi O, et al. Identification and selection of cardiomyocytes during human embryonic stem cell differentiation. FASEB J 2007; 21:2551-2563. (Pubitemid 47230684)
14. Kita-Matsuo H, Barcova M, Prigozhina N, et al. Lentiviral vectors and protocols for creation of stable hESC lines for fluorescent tracking and drug resistance selection of cardiomyocytes. PLoS One 2009; 4:e5046.
15. Xu XQ, Soo SY, Sun W, Zweigerdt R. Global expression profile of highly enriched cardiomyocytes derived from human embryonic stem cells. Stem Cells 2009; 27:2163-2174.
16. Snir M, Kehat I, Gepstein A, et al. Assessment of the ultrastructural and proliferative properties of human embryonic stem cell-derived cardiomyocytes. Am J Physiol Heart Circ Physiol 2003; 285:H2355-H2363. (Pubitemid 37443051)
17. Binah O, Dolnikov K, Sadan O, et al. Functional and developmental properties of human embryonic stem cells-derived cardiomyocytes. J Electrocardiol 2007; 40 (Suppl 6):S192-S196. (Pubitemid 350052075)
18. Germanguz I, Sedan O, Zeevi-Levin N, et al. Molecular characterization and functional properties of cardiomyocytes derived from human inducible pluripotent stem cells. J Cell Mol Med 2011; 15:38-51.
19. Tanaka T, Tohyama S, Murata M, et al. In vitro pharmacologic testing using human induced pluripotent stem cell-derived cardiomyocytes. Biochem Biophys Res Commun 2009; 385:497-502.
20. Limongelli G, Pacileo G, Marino B, et al. Prevalence and clinical significance of cardiovascular abnormalities in patients with the LEOPARD syndrome. Am J Cardiol 2007; 100:736-741. (Pubitemid 47223154)
21. Sarkozy A, Digilio MC, Dallapiccola B. Leopard syndrome. Orphanet J Rare Dis 2008; 3:13.
22. Tartaglia M, Mehler EL, Goldberg R, et al. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet 2001; 29:465-468. (Pubitemid 34326699)
23. Digilio MC, Conti E, Sarkozy A, et al. Grouping of multiple-lentigines/ LEOPARD and Noonan syndromes on the PTPN11 gene. Am J Hum Genet 2002; 71:389-394. (Pubitemid 34800254)
24. Fragale A, Tartaglia M, Wu J, Gelb BD. Noonan syndrome-associated SHP2/PTPN11 mutants cause EGF-dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation. Hum Mutat 2004; 23:267-277. (Pubitemid 38337891)
25. Kontaridis MI, Swanson KD, David FS, et al. PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects. J Biol Chem 2006; 281:6785-6792. (Pubitemid 43847615)
26. Oishi K, Zhang H, Gault WJ, et al. Phosphatase-defective LEOPARD syndrome mutations in PTPN11 gene have gain-of-function effects during Drosophila development. Hum Mol Genet 2008; 18:193-201.
27. Carvajal-Vergara X, Sevilla A, D'Souza SL, et al. Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome. Nature 2010; 465:808-812.
28. Crotti L, Celano G, Dagradi F, Schwartz PJ. Congenital long QT syndrome. Orphanet J Rare Dis 2008; 3:18.
29. Moretti A, Bellin M, Welling A, et al. Patient-specific induced pluripotent stemcell models for long-QT syndrome. NEJM 2010; 363:1397-1409
30. Itzhaki I, Maizels L, Huber I, et al. Modelling the long QT syndrome with induced pluripotent stem cells. Nature 2011 [Epub ahead of print].
31. Ieda M, Fu JD, Delgado-Olguin P, et al. Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors. Cell 2010; 142:375-386.
32. Efe JA, Hilcove S, Kim J, et al. Conversion of mouse fibroblasts into cardiomyocytes using a direct reprogramming strategy. Nat Cell Biol 2011 [Epub ahead of print].
33. Bu L, Jiang X, Martin-Puig S, et al. Human ISL1 heart progenitors generate diverse multipotent cardiovascular cell lineages. Nature 2009; 460:113-117.
34. Moretti A, Bellin M, Jung CB, et al. Mouse and human induced pluripotent stem cells as a source for multipotent Isl1+ cardiovascular progenitors. FASEB J 2010; 24:700-711.
35. Yokoo N, Baba S, Kaichi S, et al. The effects of cardioactive drugs on cardiomyocytes derived from human induced pluripotent stem cells. Biochem Biophys Res Commun 2009; 387:482-488.
36. Dick E, Rajamohan D, Ronksley J, Denning C. Evaluating the utility of cardiomyocytes from human pluripotent stem cells for drug screening. Biochem Soc Trans 2010; 38:1037-1045.